Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis
Osteoporos Int. 2016 Jun;27(6):1989-9827 randomized controlled trials that examined 9 different active treatments were included in this network meta-analysis to evaluate the efficacy of various treatments compared to placebo plus calcium and vitamin D in the treatment of patients with glucocorticoid-induced osteoporosis. Outcomes assessed in this network meta-analysis were incidence of vertebral fractures, incidence of non-vertebral fractures, and bone mineral density at the lumbar spine and femoral neck. The results of this analysis indicate that only etidronate, risedronate, and teriparatide were associated with a significantly decreased risk of vertebral fracture relative to placebo plus calcium and vitamin D. No treatments demonstrated a reduction in the risk of non-vertebral fracture when compared to placebo plus calcium and vitamin D.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics